2026-05-18T16:10:40Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/556022025-02-13T10:09:32Zcom_10324_40357com_10324_952com_10324_894col_10324_40358

Katsinas, Nicolaos Gehlsen, Uta García Posadas, Laura Rodríguez Rojo, Soraya Steven, Philipp González García, María Jesús Enriquez De Salamanca Aladro, Amalia Ojo - Enfermedades y defectos - Tratamiento Síndrome de ojo seco Aceite de oliva Aceite de oliva - Análisis Producción Científica Dry eye (DED) is a prevalent disease with immune-mediated inflammation as the principal pathophysiological etiology. Olive pomace, the major by-product of the olive oil industry, is rich in high-value polyphenols. Their anti-inflammatory and immunomodulatory activities were determined on human CD4+ T cells (hTCD4+) and in a DED animal model. The viability of hTCD4+ cells isolated from peripheral blood and activated with phytohemagglutinin-M was evaluated after treatment for 48 h with an olive pomace extract (OPT3, 0.10–0.40 mg/mL) and its major compound, hydroxytyrosol (25–100 μM). Regarding the DED animal model, 100 μM hydroxytyrosol, 0.20 mg/mL OPT3, or vehicle (borate buffer) were topically administered to 14 days-desiccating stress-exposed (constant airflow/scopolamine administration) C57BL/6 mice. Tear volume, corneal fluorescein staining (CFS), CD4+, and CD8+ T cell count in lymph nodes (flow cytometry), and IP-10 and TNF-α gene expression (qRT-PCR) in the cornea, conjunctiva, and lacrimal glands were evaluated. OPT3 (0.2–0.4 mg/mL) and hydroxytyrosol (100 μM) significantly reduced hTCD4+ proliferation. In mice, both treatments reduced lacrimal gland IP-10 gene expression. OPT3 also decreased CFS, and conjunctival IP-10 and corneal TNF-α gene expression. In lymph nodes, hydroxytyrosol reduced CD3+, OPT3, and CD8+ count. Thus, a high-value application as a promising DED protection was proposed for olive pomace. 2022-09-23 2022-09-23 2022 info:eu-repo/semantics/article Journal of Clinical Medicine, 2022, Vol. 11, Nº. 16, 17 pp. 2077-0383 https://uvadoc.uva.es/handle/10324/55602 10.3390/jcm11164703 1 16 17 Journal of Clinical Medicine 11 2077-0383 eng https://www.mdpi.com/2077-0383/11/16/4703 info:eu-repo/grantAgreement/EC/H2020/765608 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ © 2022 The Authors Atribución 4.0 Internacional MDPI